Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Barbro Dahlen
With
Karolinska Institutet
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Female or male aged 18 to 55 years inclusive
A history of asthma for at least 6 months with at least one of the following:
* response to standard asthma treatment
* episodic wheezing
* change in lung function over short periods of time
A positive methacholine challenge test as evidenced by a PD20 ≤7256 µg cumulated dose within 8 weeks prior to screening or at the screening visit.
Stable intermittent asthma, only using bronchodilator therapy as needed for the last 4 weeks.
FEV1 ≥ 75% of predicted.
A positive skin prick test to pollen (grass, birch, mugwort) or animal dander (dog, cat)
You may not be if
Known or suspected hypersensitivity to coxibs
Any significant respiratory disease other than asthma
Respiratory tract infection within 4 weeks before inclusion.
Current or former smoker within the last year and a smoking history of \>4 packyears
Pregnancy/breastfeeding
Use of:
* inhaled glucocorticosteroid treatment or use of oral corticosteroids for the last 8 weeks prior to inclusion or during the study.
* inhaled long-acting or oral beta2-agonists, anticholinergic bronchodilators, cromones, antihistamines, theophyllines and antileukotrienes within 2 weeks of screening or during the study.
* paracetamol, NSAIDs or any other antiinflammatory drugs the last 2 weeks prior to inclusion or during the study.
* need of any other regular drug treatment that may interfere with the study outcomes.
BMI \>30 kg/m2.
Use of any beta-blocking agent
Any non-asthma-related, clinically significant abnormal finding in physical and/or vital signs, and/or in hematology or blood chemistry tests at visit 1, which in the opinion of the investigator, may put the patient at risk because of participation in the study.
